FI83310B - Foerfarande foer framstaellning av terapeutiskt aktiva 4,5-substituerade 2-/3-/4-(halogenfenyl)-1- piperazinyl/propyl/-2,4-dihydro-3h-1,2,4-triazol-3-onderivat. - Google Patents

Foerfarande foer framstaellning av terapeutiskt aktiva 4,5-substituerade 2-/3-/4-(halogenfenyl)-1- piperazinyl/propyl/-2,4-dihydro-3h-1,2,4-triazol-3-onderivat. Download PDF

Info

Publication number
FI83310B
FI83310B FI843779A FI843779A FI83310B FI 83310 B FI83310 B FI 83310B FI 843779 A FI843779 A FI 843779A FI 843779 A FI843779 A FI 843779A FI 83310 B FI83310 B FI 83310B
Authority
FI
Finland
Prior art keywords
formula
compound
acid
piperazinyl
propyl
Prior art date
Application number
FI843779A
Other languages
English (en)
Finnish (fi)
Other versions
FI843779A0 (fi
FI83310C (sv
FI843779L (fi
Inventor
Joseph P Yevich
Richard E Gammans
David W Smith
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24145128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI83310(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of FI843779A0 publication Critical patent/FI843779A0/fi
Publication of FI843779L publication Critical patent/FI843779L/fi
Application granted granted Critical
Publication of FI83310B publication Critical patent/FI83310B/fi
Publication of FI83310C publication Critical patent/FI83310C/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (2)

1. Förfarande för framställning av ett terapeutiskt aktivt 4, 5-substituerat 2-[3-[4-( halogenfenyl )-l-piperazi-5 nyl]propyl]-2,4-dihydro-3H-l,2,4-triazol-3-onderivat med formeln I r° \ , y
0 I väri R är väte eller fenylsubstituerad lägre alkyl och Y 15 är halogen, eller ett farmaceutiskt godtagbart sait därav, kännetecknat därav, att (a) hydrazin omsätts med en lämpligt skyddad mjölk-syraester med formeln VI ™ OP 20 , /Αγ·"" 0CH3 0 VI 25 väri P är med fenyl substituerad lägre alkyl eller en syr-alabil skyddsgrupp (företrädesvis en metoximetylgrupp), Ca_4-alkyl eller lägre alkylfenyl, under sädana betingelser att det bildas en hydrazidmellanprodukt med formeln V 30 OP NHNH2
0 V 35 II 23 8 3 3 1 0 b) nämnda förening med formeln V omsätts med en förening med formeln VII /QVo-(ch2)2-n-c*o 5 '—' vil under sddana reaktionsbetingelser att det bildas en förening med formeln IV 10 r—\ ** OP \Q/~°- ( ch2 ) 2-n^^nhnh^^jI^ O O 15 c) nämnda förening med formeln IV uppvärms med dterlopp under cykliseringsbetingelser, sä att det bildas en förening med formeln III 20 ^^-0-(CH2)2-N .NH III o ooh 25 d) nämnda förening med formeln III alkyleras med 1- (3-klorpropyl)-4-(halogenfenyl)piperazin, ifall P i formeln VI är en syralabil skyddsgrupp, avspjälkas denna ge-nom att behandla den erhällna föreningen med en utspädd syra, sd att det bildas en förening med formeln I, väri R 30 är väte, och e) om sd önskas, omvandlas den erhdllna föreningen med formeln I tili ett farmaceutisk godtagbart sait därav genom omsättning med en lämplig organisk eller oorganisk syra, företrädesvis i en lösning. 24 83310
2. Förfarande enligt patentkravet 1 för framställ-ning av 2-[3-[4-(3-klorfenyl)-l-piperazinyl]propyl]-5-(l-hydroxietyl)-2,4-dihydro-4-(2-fenoxietyl)-3H-l,2,4-tri-azol-3-on eller farmaceutiskt godtagbara syraadditionssal-5 ter därav.
FI843779A 1983-09-30 1984-09-26 Förfarande för framställning av terapeutiskt aktiva 4,5-substituerade 2-/3-/4-(halogenfenyl)-1-piperazinyl/propyl/-2,4-dihydro-3H-1,2,4-tria zol-3-onderivat FI83310C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53802783 1983-09-30
US06/538,027 US4613600A (en) 1983-09-30 1983-09-30 Antidepressant 1,2,4-triazolone compounds

Publications (4)

Publication Number Publication Date
FI843779A0 FI843779A0 (fi) 1984-09-26
FI843779L FI843779L (fi) 1985-03-31
FI83310B true FI83310B (fi) 1991-03-15
FI83310C FI83310C (sv) 1991-06-25

Family

ID=24145128

Family Applications (1)

Application Number Title Priority Date Filing Date
FI843779A FI83310C (sv) 1983-09-30 1984-09-26 Förfarande för framställning av terapeutiskt aktiva 4,5-substituerade 2-/3-/4-(halogenfenyl)-1-piperazinyl/propyl/-2,4-dihydro-3H-1,2,4-tria zol-3-onderivat

Country Status (25)

Country Link
US (1) US4613600A (sv)
JP (1) JPS60100560A (sv)
KR (1) KR880002624B1 (sv)
AT (1) AT387963B (sv)
AU (1) AU561460B2 (sv)
BE (1) BE900714A (sv)
CA (1) CA1237723A (sv)
CH (1) CH661924A5 (sv)
CY (1) CY1541A (sv)
DE (1) DE3435745C2 (sv)
DK (1) DK169546B1 (sv)
ES (1) ES536286A0 (sv)
FI (1) FI83310C (sv)
FR (1) FR2552759B1 (sv)
GB (1) GB2147297B (sv)
GR (1) GR80475B (sv)
HK (1) HK37391A (sv)
IE (1) IE58084B1 (sv)
IT (1) IT1178522B (sv)
LU (1) LU85561A1 (sv)
MY (1) MY102123A (sv)
NL (1) NL8402946A (sv)
SE (1) SE465928B (sv)
YU (1) YU45667B (sv)
ZA (1) ZA847589B (sv)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
YU44721B (en) * 1983-11-30 1990-12-31 Bristol Myers Co Process for obtaining 4-(2-phenoxyethyl)-1,2,4-triazolone
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5504086A (en) * 1989-10-17 1996-04-02 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering trifluorobenzodiazepines, propoxyphene, and nefazodone
US5256664A (en) * 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
DE4425144A1 (de) * 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
US6403593B1 (en) 1995-07-14 2002-06-11 Abbott Laboratories Triazole compounds and the use thereof
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
US6469008B2 (en) 1999-04-09 2002-10-22 Sepracor Inc. (R)-hydroxynefazodone antipsychotic therapy
WO2000061129A2 (en) * 1999-04-09 2000-10-19 Sepracor Inc. S-hydroxynefazodone
US6586437B2 (en) 1999-04-09 2003-07-01 Sepracor Inc. (S)-hydroxynefazodone antipsychotic therapy
AU4215300A (en) 1999-04-09 2000-11-14 Sepracor, Inc. R-hydroxynefazodone
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
EP2392258B1 (en) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-informatics system
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
US9339500B2 (en) * 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
WO2010129819A2 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
AU2012304407A1 (en) 2011-09-09 2014-04-24 Children's Hospital & Research Center Oakland Topical itraconazole formulations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
IT1052119B (it) * 1972-10-16 1981-06-20 Sigma Tau Ind Farmaceuti Derivati del triazolinone e procedimento per la loro preparazione
US4338317A (en) * 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants

Also Published As

Publication number Publication date
KR850002270A (ko) 1985-05-10
IE58084B1 (en) 1993-06-30
DK468284D0 (da) 1984-09-28
DE3435745C2 (de) 1994-11-03
US4613600A (en) 1986-09-23
AT387963B (de) 1989-04-10
GB8424535D0 (en) 1984-11-07
GB2147297A (en) 1985-05-09
FR2552759A1 (fr) 1985-04-05
SE8404869D0 (sv) 1984-09-28
IT1178522B (it) 1987-09-09
LU85561A1 (fr) 1985-06-04
DK468284A (da) 1985-03-31
GR80475B (en) 1985-01-31
AU3364884A (en) 1985-04-04
IE842476L (en) 1985-03-30
JPS60100560A (ja) 1985-06-04
SE465928B (sv) 1991-11-18
FR2552759B1 (fr) 1988-10-07
YU45667B (sh) 1992-07-20
ATA310884A (de) 1988-09-15
FI843779A0 (fi) 1984-09-26
BE900714A (fr) 1985-03-28
YU172184A (en) 1986-10-31
DE3435745A1 (de) 1985-04-11
NL8402946A (nl) 1985-04-16
FI83310C (sv) 1991-06-25
HK37391A (en) 1991-05-24
DK169546B1 (da) 1994-11-28
ES8601966A1 (es) 1985-11-16
MY102123A (en) 1992-03-31
GB2147297B (en) 1987-04-15
ES536286A0 (es) 1985-11-16
CH661924A5 (de) 1987-08-31
CY1541A (en) 1991-03-22
CA1237723A (en) 1988-06-07
ZA847589B (en) 1985-05-29
IT8422922A0 (it) 1984-09-28
SE8404869L (sv) 1985-03-31
JPH0542435B2 (sv) 1993-06-28
FI843779L (fi) 1985-03-31
AU561460B2 (en) 1987-05-07
KR880002624B1 (ko) 1988-12-07

Similar Documents

Publication Publication Date Title
FI83310B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 4,5-substituerade 2-/3-/4-(halogenfenyl)-1- piperazinyl/propyl/-2,4-dihydro-3h-1,2,4-triazol-3-onderivat.
US4487773A (en) 1,2,4-Triazol-3-one antidepressants
FR2501690A1 (fr) Derives heterocycliques du type 1,2,4-triazole, leur preparation et leur application pharmacologique
HU224197B1 (hu) Alfa2-receptorokra ható imidazolszármazékok
NZ582520A (en) Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
EP0568437B1 (en) Antidepressant 3-Halophenylpiperazinyl-propyl Derivatives of Substituted Triazolones and Triazoldiones
US4576957A (en) N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas
JP2840288B2 (ja) 置換1―(1h―イミダゾール―4―イル)アルキル―ベンズアミド
MX2011001070A (es) Nuevos derivados de difenil 1,2,3-triazol utiles como moduladores de los receptores de acetilcolina nicotinicos.
HU185647B (en) Process for producing new 4h-1,2,4-triazole derivatives
EP1242389B1 (fr) Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
HU206684B (en) Process for producing substituted 1h-imidazols and pharmaceutical compositions containing them as active component
EP1710240A1 (fr) Dérives de pipérazine et leur utilisation comme inhibiteurs de recapture de la sérotonine ou comme antagonistes de neurokinine
US4575555A (en) 4-(3-Chlorophenyl)-1,2,3,6-tetrahydropyridine derivative
KR100254690B1 (ko) 트라조돈의 알킬 유도체
US6121264A (en) Imidazole-substituted quinoxalinedione derivatives
HUT54125A (en) Process for producing triazine derivatives and pharmaceutical compositions comprising same
EP0821676B1 (en) 3-phenyl-1,4-dialkyl-1,2,4-triazolium salts and their use as antidepressants
FR2578842A1 (fr) Nouveaux derives de la pyrrolo(1,2-a) azepinone, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2134251A1 (en) N-substituted imidazole derivatives

Legal Events

Date Code Title Description
MA Patent expired

Owner name: BRISTOL-MYERS SQUIBB COMPANY

MA Patent expired